MedPath

FCH PET/MRI Parathyroid Localization

Not Applicable
Completed
Conditions
18F-fluorocholine
Positron-Emission Tomography
Hyperparathyroidism, Primary
Interventions
Diagnostic Test: [F-18]-FCH PET/MRI
Registration Number
NCT03324893
Lead Sponsor
University Health Network, Toronto
Brief Summary

A prospective trial comparing the accuracy of \[F-18\]-FCH PET/MRI to US and 99mTc-MIBI SPECT/CT for pre-operative parathyroid localization in patients with primary hyperparathyroidism

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
47
Inclusion Criteria
  • Age ≥ 18 years
  • Biochemically proven primary hyperparathyroidism
  • Indication for parathyroidectomy as per institutional guidelines
Exclusion Criteria
  • Contraindication for MRI as per current institutional guidelines.
  • Contraindication for Gadolinium injection as per current institutional guidelines.
  • Renal failure
  • Inability to lie supine for at least 45 minutes.
  • Any participant who is pregnant or breastfeeding.
  • Participants receiving erythropoietin (i.e. for hemochromatosis; might lead to false negative results due to stimulation of bone marrow metabolism)
  • Familial HPT syndromes
  • Participant currently being treated with any cytotoxic chemotherapy

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
[F18]-FCH PET/MRI[F-18]-FCH PET/MRIPatients with primary hyperparathyroidism planned for parathyroidectomy
Primary Outcome Measures
NameTimeMethod
Accuracy of [F-18]-FCH PET/MRI in localization of diseased parathyroid gland1 month postoperatively

Value of \[F-18\]-FCH PET/MRI next to Ultrasound of the Neck and 99mTc-MIBI SPECT/CT in determining which of the four parathyroid glands

Reference standards:

* Intra-operative location of the hyper functioning gland by inspection and post-operative pathological confirmation.

* Determination of biochemical cure per usual standard of care: intraoperative PTH and calcium and PTH postoperatively.

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (1)

UHN

🇨🇦

Toronto, Ont, Canada

© Copyright 2025. All Rights Reserved by MedPath